Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Kiniksa Pharmaceuticals Ltd
KNSACurrent price
21.29 USD
-0.61 USD (-2.79%)
Last closed
21.81 USD
Company
www.kiniksa.com
ISIN
BMG5269C1010
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Capitalization
1 650 528 640 USD
Yield for 12 month
+37.35 %
1Y
3Y
5Y
10Y
15Y
KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. Address: 23 Old Bond Street, London, United Kingdom, WIS 4PZ
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
36 USDP/E ratio
–Dividend Yield
–Current Year
+270 259 000 USD
Last Year
+220 180 000 USD
Current Quarter
+112 214 000 USD
Last Quarter
+108 631 000 USD
Current Year
+179 219 000 USD
Last Year
+173 214 000 USD
Current Quarter
+62 798 000 USD
Last Quarter
+66 176 000 USD
Key Figures KNSA
1 year
3 years
5 years
10 years
EBITDA
-24 401 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-3.16 %
PEG Ratio
–
Return On Equity TTM
-2.15 %
Wall Street Target Price
36 USD
Revenue TTM
384 097 984 USD
Book Value
6.06 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
67.4 %
Dividend Yield
–
Gross Profit TTM
173 214 000 USD
Earnings per share
-0.12 USD
Diluted Eps TTM
-0.12 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
550 %
Profit Margin
-2.36 %
Dividend Analytics KNSA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KNSA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:1
Payout Ratio
–
Last Split Date
28.06.2024
Dividend Date
–
Stock Valuation KNSA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
3.7459
Price Sales TTM
4.2972
Enterprise Value EBITDA
-44.9276
Price Book MRQ
3.7802
Financials KNSA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators KNSA
For 52 weeks
15.05 USD
28.15 USD
50 Day MA
24.96 USD
Shares Short Prior Month
4 087 264
200 Day MA
21.66 USD
Short Ratio
8.53
Shares Short
4 006 718
Short Percent
12.42 %
BeatStart